Vagus Nerve & Rheumatoid Arthritis: Neuroimmune Modulation Trial

Okay, here’s⁣ a breakdown of the information from the provided text, focusing on key findings related to efficacy (results) and safety:

Efficacy (Results)

* ACR20 Response: At ⁤6 months, Arm ‍1 (higher stimulation) showed considerably higher ACR20 response rates compared to Arm 2 (lower stimulation). Specifically:
⁣ * ‍ ‍ Month 1: 48.1% vs. 28.3% (P = 0.0097)
‍ *⁢ ⁣ ⁣Month 2: 54.8% vs. 31.0% (P = 0.0009)
* ⁣ Month 3: 57.9% vs.⁢ 34.5% (P = 0.0131)
* EULAR Good/Moderate⁤ Response: Similar ⁣to ACR20, Arm 1 had significantly higher EULAR response rates at ⁤months 1, 2, and 3.
* DAS28-CRP MCID: ⁣ Arm ⁤1 showed a higher⁤ percentage of patients achieving the MCID (Minimal Clinically ⁤Vital Difference) on the DAS28-CRP scale at months 1, 2, and 3.
* HAQ-DI MCID: Arm 1 also showed a higher percentage of patients‍ achieving the MCID ⁤on the HAQ-DI scale at months 1, 2, and 3.
* 12-Month Follow-up (Nonresponder Imputation): Using nonresponder imputation, the ACR20 response was around 50-51% in both arms, EULAR good/moderate response was around⁢ 70-71%,⁤ DAS28-CRP ‍MCID was 60.3% (Arm 1) and 55.8% (Arm 2), and HAQ-DI MCID was around 55% in both arms.

Safety

* No Serious Issues: No deaths or unanticipated adverse⁤ device effects were reported.
* Implantation-Related Events: Adverse events related to the implantation procedure occurred in 15.6% of ‍patients (52 events). These were generally mild to moderate and consistent with other similar devices.
*⁤ Hoarseness/Vocal Cord Issues: ⁣ The most common implantation-related events were mild⁢ to moderate hoarseness, categorized as vocal cord paresis (4.5%) or dysphonia (2.9%).These⁣ resolved over time, with some patients receiving fillers or voice therapy. No surgeries were needed.
* Surgical Site⁢ Issues: 5.4% of patients experienced mild to moderate issues at the surgical site (swelling,hypoesthesia,stitch abscess/infection,pain,erythema,suture complication).
* stimulation-Related Events: Stimulation was generally⁤ well-tolerated.
* Mild to⁣ moderate pain occurred in 4.2% ⁤of patients during the controlled period and 4.6% during long-term follow-up.
* These events typically resolved by adjusting stimulation strength or timing, without stopping therapy.

P-value Significance:

* P* < 0.025
* ⁣ P < 0.01
* P* ‍< 0.001

In essence, the ⁢study suggests that the higher stimulation⁤ arm (Arm 1) demonstrated significantly better clinical responses in the early phases of the trial (months 1-3). While the differences appeared to lessen ⁣at 12 months (with nonresponder imputation), the device was generally safe and well-tolerated.